Updates in the Evolving Diffuse Large B-Cell Lymphoma Treatment Landscape
Matthew Matasar, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, provides expert insights into the current and evolving “potentially practice-changing” clinical trial research landscape for the treatment of patients with diffuse large B-cell lymphoma (DLBCL).
Transcript:
Hi, I'm Dr Matt Matasar. I'm the Chief of Blood Disorders at the Rutgers Cancer Institute. I just wanted to share my perspective on what's coming down the pike for diffuse large B-cell lymphoma. There are a number of really potentially practice-changing first-line studies that are being designed, conducted, and deployed right now.
Some have been completed, such as the ESCALADE Trial, evaluating acalabrutinib in combination with R-CHOP in non-germinal center B-cell, or activated B-cell subtype DLBCL. But there's a lot of interest in other molecules in this context as well, including bispecific antibodies.
There's a number of first-line studies, including the OLYMPIA Trials, combining odronextamab plus CHOP, studies combining glofitamab or obinutuzumab in the first-line context as well. There will be a lot of interest in CAR T-cell therapy in the first-line setting. There's a study being conducted by Allogene and investigators partnering with Allogene, looking at the use of their allogeneic CAR T-cell product as consolidation for MRD-positive DLBCL, following first-line anthracycline-based chemo-immunotherapy.
With all the studies as well, including tafasitamb and lenalidomide in combination with R-CHOP, it's a very exciting and promising time in DLBCL. And it's possible that these next few years will lead us to a very different-looking landscape for patients with newly diagnosed DLBCL.
Again, my name's Matt Matasar from Rutgers Cancer Institute, and thanks for your interest.
